These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

871 related articles for article (PubMed ID: 18852116)

  • 1. Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling.
    Wilhelm SM; Adnane L; Newell P; Villanueva A; Llovet JM; Lynch M
    Mol Cancer Ther; 2008 Oct; 7(10):3129-40. PubMed ID: 18852116
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preclinical and clinical development of the oral multikinase inhibitor sorafenib in cancer treatment.
    Strumberg D
    Drugs Today (Barc); 2005 Dec; 41(12):773-84. PubMed ID: 16474853
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5.
    Liu L; Cao Y; Chen C; Zhang X; McNabola A; Wilkie D; Wilhelm S; Lynch M; Carter C
    Cancer Res; 2006 Dec; 66(24):11851-8. PubMed ID: 17178882
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery and development of sorafenib: a multikinase inhibitor for treating cancer.
    Wilhelm S; Carter C; Lynch M; Lowinger T; Dumas J; Smith RA; Schwartz B; Simantov R; Kelley S
    Nat Rev Drug Discov; 2006 Oct; 5(10):835-44. PubMed ID: 17016424
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sorafenib, a multikinase inhibitor, is effective in vitro against non-Hodgkin lymphoma and synergizes with the mTOR inhibitor rapamycin.
    Ramakrishnan V; Timm M; Haug JL; Kimlinger TK; Halling T; Wellik LE; Witzig TE; Rajkumar SV; Adjei AA; Kumar S
    Am J Hematol; 2012 Mar; 87(3):277-83. PubMed ID: 22190165
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sorafenib.
    Hasskarl J
    Recent Results Cancer Res; 2010; 184():61-70. PubMed ID: 20072831
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sorafenib, a dual Raf kinase/vascular endothelial growth factor receptor inhibitor has significant anti-myeloma activity and synergizes with common anti-myeloma drugs.
    Ramakrishnan V; Timm M; Haug JL; Kimlinger TK; Wellik LE; Witzig TE; Rajkumar SV; Adjei AA; Kumar S
    Oncogene; 2010 Feb; 29(8):1190-202. PubMed ID: 19935717
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis.
    Wilhelm SM; Carter C; Tang L; Wilkie D; McNabola A; Rong H; Chen C; Zhang X; Vincent P; McHugh M; Cao Y; Shujath J; Gawlak S; Eveleigh D; Rowley B; Liu L; Adnane L; Lynch M; Auclair D; Taylor I; Gedrich R; Voznesensky A; Riedl B; Post LE; Bollag G; Trail PA
    Cancer Res; 2004 Oct; 64(19):7099-109. PubMed ID: 15466206
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined tyrosine and serine/threonine kinase inhibition by sorafenib prevents progression of experimental pulmonary hypertension and myocardial remodeling.
    Klein M; Schermuly RT; Ellinghaus P; Milting H; Riedl B; Nikolova S; Pullamsetti SS; Weissmann N; Dony E; Savai R; Ghofrani HA; Grimminger F; Busch AE; Schäfer S
    Circulation; 2008 Nov; 118(20):2081-90. PubMed ID: 18955668
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting Raf-kinase: molecular rationales and translational issues.
    Caraglia M; Tassone P; Marra M; Budillon A; Venuta S; Tagliaferri P
    Ann Oncol; 2006 Jun; 17 Suppl 7():vii124-7. PubMed ID: 16760274
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Induction of Bim expression contributes to the antitumor synergy between sorafenib and mitogen-activated protein kinase/extracellular signal-regulated kinase kinase inhibitor CI-1040 in hepatocellular carcinoma.
    Ou DL; Shen YC; Liang JD; Liou JY; Yu SL; Fan HH; Wang DS; Lu YS; Hsu C; Cheng AL
    Clin Cancer Res; 2009 Sep; 15(18):5820-8. PubMed ID: 19737956
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sorafenib and sunitinib in the treatment of advanced non-small cell lung cancer.
    Gridelli C; Maione P; Del Gaizo F; Colantuoni G; Guerriero C; Ferrara C; Nicolella D; Comunale D; De Vita A; Rossi A
    Oncologist; 2007 Feb; 12(2):191-200. PubMed ID: 17296815
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Myelosuppression and kinase selectivity of multikinase angiogenesis inhibitors.
    Kumar R; Crouthamel MC; Rominger DH; Gontarek RR; Tummino PJ; Levin RA; King AG
    Br J Cancer; 2009 Nov; 101(10):1717-23. PubMed ID: 19844230
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sorafenib: complexities of Raf-dependent and Raf-independent signaling are now unveiled.
    Matsuda Y; Fukumoto M
    Med Mol Morphol; 2011 Dec; 44(4):183-9. PubMed ID: 22179180
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: a review of four phase I trials in patients with advanced refractory solid tumors.
    Strumberg D; Clark JW; Awada A; Moore MJ; Richly H; Hendlisz A; Hirte HW; Eder JP; Lenz HJ; Schwartz B
    Oncologist; 2007 Apr; 12(4):426-37. PubMed ID: 17470685
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sorafenib.
    Rini BI
    Expert Opin Pharmacother; 2006 Mar; 7(4):453-61. PubMed ID: 16503817
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of Raf kinase in cancer: therapeutic potential of targeting the Raf/MEK/ERK signal transduction pathway.
    Gollob JA; Wilhelm S; Carter C; Kelley SL
    Semin Oncol; 2006 Aug; 33(4):392-406. PubMed ID: 16890795
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sorafenib (BAY 43-9006, Nexavar), a dual-action inhibitor that targets RAF/MEK/ERK pathway in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor vasculature.
    Adnane L; Trail PA; Taylor I; Wilhelm SM
    Methods Enzymol; 2006; 407():597-612. PubMed ID: 16757355
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of sorafenib on murine liver regeneration.
    Hora C; Romanque P; Dufour JF
    Hepatology; 2011 Feb; 53(2):577-86. PubMed ID: 21274878
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sorafenib inhibits the angiogenesis and growth of orthotopic anaplastic thyroid carcinoma xenografts in nude mice.
    Kim S; Yazici YD; Calzada G; Wang ZY; Younes MN; Jasser SA; El-Naggar AK; Myers JN
    Mol Cancer Ther; 2007 Jun; 6(6):1785-92. PubMed ID: 17575107
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 44.